At present, two anti-angiogenic drugs are being tested in the phase III setting for men with prostate cancer, carbozantinib (a dual VEGFR2/MET inhibitor) and tasquinimod (down-regulator of HIF-1α), which previously showed beneficial and encouraging results on phase II trials [45]. This evidence concerns the gene HIF1A and prostate cancer.